Pfizer Inc. has agreed to acquire obesity drug developer Metsera for $10 billion, concluding a week-long bidding battle with Novo Nordisk. The deal, valued at $86.25 per share, includes $65.60 in cash and a contingent value right of up to $20.65 per share. Metsera’s board has recommended that shareholders approve the merger, which is expected […]Continue Reading
